Form 4: Eli Lilly Executive Jacob Van Naarden Reports Stock Transactions

EVP & President of Lilly Oncology, Jacob Van Naarden, reports acquisition and disposal of Eli Lilly & Co. common stock and restricted stock units.

Summary

• Jacob Van Naarden, EVP & President of Lilly Oncology, filed a Form 4 detailing changes in beneficial ownership of Eli Lilly & Co. stock.
• On February 10, 2025, Van Naarden acquired 6,103.824 shares of common stock at $868.88 per share.
• Van Naarden also disposed of an unspecified amount of common stock on the same date.
• Following the reported transactions, Van Naarden directly owns 19,561.985 shares of common stock.
• Van Naarden indirectly owns 4,302 shares through his spouse and 4,342 shares through the Van Naarden Family Trust.
• Additionally, Van Naarden acquired 4,108 restricted stock units, each representing a contingent right to receive one share of Eli Lilly and Company common stock, exercisable on February 1, 2026, and expiring on February 1, 2026.
• Van Naarden disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document primarily reports stock transactions, with no explicit positive or negative commentary on the company's performance.

Positives

• The acquisition of restricted stock units indicates confidence in the company's future performance.

Negatives

• The document indicates the disposal of an unspecified amount of common stock.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Executive stock ownership is common across the pharmaceutical industry.
• Comparing Van Naarden's holdings and transactions to those of executives at companies like Pfizer (PFE), Merck (MRK), and Johnson & Johnson (JNJ) could provide context.
• The size and frequency of these transactions are typical for executives at large, publicly traded companies.

Stakeholder Impact

• The reported transactions provide transparency to shareholders regarding executive stock ownership.
• The transactions may influence investor sentiment, depending on the perceived reasons behind the buying and selling activity.

Key Dates